MedTrace Logo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 607

Last updated 2026-02-27

No results posted yet for this study

Summary

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Conditions

  • Stable Nonsegmental Vitiligo
  • Active Nonsegmental Vitiligo

Interventions

DRUG

Ritlecitinib

50 mg capsule

DRUG

Placebo

Matching capsule

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2026-02-05
Completion
2026-02-05
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • China
  • Germany
  • Italy
  • Japan
  • Mexico
  • Poland
  • South Africa
  • South Korea
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05583526 on ClinicalTrials.gov